ArticlePloS one2013
TOX3 mutations in breast cancer.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Molecular signatures of breast cancer in the Iranian population: a review of cell growth and cell cycle regulators.Journal of cancer research and clinical oncology · 2025Pooled it
- Association of single nucleotide polymorphism rs3803662 with the risk of breast cancer.Scientific reports · 2016Pooled it
- Low expression of TOX predicts poor prognosis of patients with breast cancer in the real world: A retrospective study.Heliyon · 2025Article
- Understanding genetic variations associated with familial breast cancer.World journal of surgical oncology · 2024Review
- Revealing the impact of TOX3 on osteoarthritis: insights from bioinformatics.Frontiers in medicine · 2023Article
- Clinical characterization, genetic profiling, and immune infiltration of TOX in diffuse gliomas.Journal of translational medicine · 2020Article
- AnJournal of genetics · 2019Article
- Two novel genes TOX3 and COL21A1 in large extended Malay families with nonsyndromic cleft lip and/or palate.Molecular genetics & genomic medicine · 2019Article
- Correlation between Candidate Single Nucleotide Variants and Several Clinicopathological Risk Factors Related to Breast Cancer in Jordanian Women: A Genotype-Phenotype Study.Journal of Cancer · 2019Article
- Pan-cancer screen for mutations in non-coding elements with conservation and cancer specificity reveals correlations with expression and survival.NPJ genomic medicine · 2018Article
- Integrated Theory- and Data-driven Feature Selection in Gene Expression Data Analysis.Proceedings. International Conference on Data Engineering · 2017Article
- Article
- TOX3 is expressed in mammary ER(+) epithelial cells and regulates ER target genes in luminal breast cancer.BMC cancer · 2015Article
- Molecular and clinical evidence for an ARMC5 tumor syndrome: concurrent inactivating germline and somatic mutations are associated with both primary macronodular adrenal hyperplasia and meningioma.The Journal of clinical endocrinology and metabolism · 2015Article
- TOX gene: a novel target for human cancer gene therapy.American journal of cancer research · 2015Review
- Article
- Associations of two common genetic variants with breast cancer risk in a chinese population: a stratified interaction analysis.PloS one · 2014Article
- Proteomic profile and in silico analysis in metastatic melanoma with and without BRAF mutation.PloS one · 2014Article
- Effects of lifestyle and single nucleotide polymorphisms on breast cancer risk: a case-control study in Japanese women.BMC cancer · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
TOX3 maps to 16q12, a region commonly lost in breast cancers and recently implicated in the risk of developing breast cancer. However, not much is known of the role of TOX3 itself in breast cancer biology. This is the first study to determine the importance of TOX3 mutations in breast cancers. We screened TOX3 for mutations in 133 breast tumours and identified four mutations (three missense, one in-frame deletion of 30 base pairs) in six primary tumours, corresponding to an overall mutation frequency of 4.5%. One potentially deleterious missense mutation in exon 3 (Leu129Phe) was identified in one tumour (genomic DNA and cDNA). Whilst copy number changes of 16q12 are common in breast cancer, our data show that mutations of TOX3 are present at low frequency in tumours. Our results support that TOX3 should be further investigated to elucidate its role in breast cancer biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.